Chinese Academy of Sciences

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Yangtze River Pharmaceutical Group Co., Ltd.

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Delta Electronics (shanghai) Co., Ltd

Business Objects Software Limited

Other

Fujitsu Corporation

Conopco, Inc.

Tianma Micro-electronics Co., Ltd.

General Electric Technology Gmbh

On-bright Electronics (shanghai) Co., Ltd.

Shanghai Avic Opto Electronics Co., Ltd.

Fudan University

Shpp Global Technologies B.v.

Zheng Wang

Haiying He

Weidong Li

Shuhui Chen

Xiaolin Li

Yi Zhang

Yuan Chen

Fei Sun

Ling Yang

Zhi Luo

Hongwei Li

Feng Xu

Zhigan Jiang

Rui Zhao

Jian Li

Jian-Ping Ying

Fang Liu

Charles Z Ding

Yong Wang

Kai Zhou

Cong Wang

Hui Liu

Hong-Jian Gan

Zhao Wang

Yong Xu

Lie Li

Lei Zhang

Jianping Ying

Peng Zhang

Zhaokeng Cao

Ming Hsi Wang

Teng Liu

Peng Li

Jian Zhou

Bin Liu

Qian Zhang

Qing Li

Chengde Wu

Zhen Zhu

Kevin X Chen

Lei Yu

Feng Guo

Hengxu Ha

Lingyun Wu

Hongjian Gan

Tao Yu

Chaofeng Long

Xiaoxin Chen

Lifeng Qiao

Hariharan Ramalingam

Dakun Qin

Zhaozhong Ding

Songliang Wu

Yinghu Hu

Yilong Zhou

Yuhe Wang

Kuiling Ding

Weihua Shi

Linghui Wu

Minggao Zeng

Kunmin Lai

Lu Huang

Yong Tang

Xuehai Wang

Cailin Wang

Zhiyong Gong

Ning Li

Zhuowei Liu

Xiao Liu

Liang Shen

Xiaoming Wang

Yilei Chai

Ronghua Tu

Yong Zeng

Changshan Zhang

Xiuli Sun

Jie Shen

Shuying Liu

Hailiang Chen

Wenjie Sun

Zongbin Li

Yanjun Liu

Hailong Wang

Xingxing Wang

Yao Lin

Yongyue Ma

Lijuan Chen

Xiaofei Wang

Longcai Xin

Changjun Wang

Yaxun Yang

Shenyi Shi

Jiahu Wu

Lin Lu

Xia Zheng

Provided are a method and system for individualized prediction of mental illness on the basis of brain function map monkey-human cross-species migration, and a method for determining a mental illness prediction model. The method for determining a mental illness prediction model comprises the steps: (a) data acquisition; (b) preprocessing; (c) brain region selection; (d) feature construction; (e) feature screening; and (f) modeling prediction. The method and system are non-invasive and have high accuracy, high sensitivity, good specificity, and are convenient to popularize.

Method and system for individualized prediction of mental illness on basis of brain function map monkey-human cross-species migration

The present disclosure discloses a class of macrocyclic derivatives, and specifically discloses a compound shown in formula (VI), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.

Macrocyclic derivative and use thereof

USB charging system and method. For example, a USB charging system includes: a first AC-to-DC conversion unit configured to generate a first voltage and a first current; a second AC-to-DC conversion unit configured to generate a second voltage and a second current; a first USB output port corresponding to the first AC-to-DC conversion unit; a second USB output port corresponding to the second AC-to-DC conversion unit; a switch connected to the first AC-to-DC conversion unit and the second AC-to-DC conversion unit; and a control chip connected to the first AC-to-DC conversion unit and the second AC-to-DC conversion unit and configured to open the switch and close the switch; wherein the control chip is further configured to: determine whether the first USB output port is connected to a load device and whether the second USB output port is connected to a load device.

Systems and methods for power sharing related to multiport chargers

Provided are a mutant of an immunoglobulin degrading enzyme IdeE, a protein comprising the mutant, and a use of a composition and a kit in preparation of a drug for reducing the level of IgG in a subject. The mutant has amino acid substitution, N-terminal truncated and/or C-terminal truncated on one or more of positions 8, 10, 24, 59, 97, and 280 of the amino acid sequence shown in SEQ ID NO: 2, and the mutant has the function of the immunoglobulin degrading enzyme IdeE, and has higher activity and thermal stability than wild-type IdeE.

Use of mutant of immunoglobulin degrading enzyme IdeE

Display screen or portion thereof with animated graphical user interface

Disclosed are a ring-modified proline short peptide compound and the use thereof, and specifically disclosed is a compound represented by formula (X) or a pharmaceutically acceptable salt thereof.

Ring-modified proline short peptide compound and use thereof

The present disclosure provides a method for remotely controlling a personal computer (PC). from a mobile device. The method includes displaying, by a first input module operating on the mobile device, an input GUI on the mobile device. The first input module interacts with a second input module operating on the PC. The method includes, upon receiving an activation of a virtual input on the input GUI, retrieving a first simulated input that is associated with the virtual input. The method further includes transmitting the first simulated input to the second input module, wherein the second input module is configured to perform the first simulated input on the PC in response to the activation of the virtual input on the input GUI.

Virtual input device-based method and system for remotely controlling PC

Chiral spirobiindane skeleton compound and preparation method thereof is disclosed in the present invention. The spirobiindane skeleton compound of the present invention having the structure formula of I or I'; the preparation method for synthesizing the spirobiindane skeleton compound of the present invention comprising the following steps: in the presence of solvent and catalysts, the structure formula compound III reacted through intramolecular Friedel-Crafts reaction to obtain the compound of formula I; the catalyst is a Browsteric acidor Lewis acid. The preparation method of chiral fused spirobiindane skeleton compound of the present invention does not need to adopt chiral starting materials or chiral resolving agents, does not require chiral resolving steps, is simple in method, is simple in post-treatment, and is economic and environment friendly. High product yield, high product optical purity and chemical purity. The catalyst for the asymmetric reaction is obtained from the chiral spirobiindane skeleton ligand of the present invention, under the catalytic reagent of transition metal, the catalyzed hydrogenation reaction can arrive at a remarkable catalytic effect with a product yield of &#x3e;99%, and a product ee value of up to &#x3e;99%. 

Compound having chiral spirobiindane skeleton and preparation method therefor

The present invention discloses to a hydrochloride salt, a citrate salt, a phosphate salt or a sulfate salt of compound 1, the crystal forms of the aforementioned salts, and a preparation method thereof. The present invention also relates their use in the preparation of a medicament for the treatment of cerebral apoplexy or epilepsy. 

Salts and crystal forms of diaza-benzofluoranthrene compounds

The present invention relates to crystalline form A of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)-benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), a method for preparing the crystalline form A, and the use thereof. 

Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine for inhibiting toll-like receptor activity

The present disclosure discloses sodium ion channel inhibitors, pharmaceutically acceptable salts and polymorphs thereof, and uses thereof. Specifically, the present disclosure discloses a polymorph of a compound of formula (X) and a preparation method thereof. The preparation method of the present disclosure is simple in operation and suitable for industrialization. The polymorph prepared by the preparation method has advantages of good stability, low hygroscopicity and high water solubility. 

Sodium ion channel inhibitors and pharmaceutically acceptable salts and polymorphs thereof and uses thereof

Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1, 5-alpha]benzimidazole compound and the preparation method and intermediate thereof. The 4H-pyrazolo[1,5-alpha]benzimidazole compound has the structure of Compound 2. 

Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof

Disclosed are a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Crystal form of orexin receptor antagonist compound, and preparation method and application thereof

Disclosed is a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Growing community of inventors

Shanghai, China

Zheng Wang